Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés(Villa Maria Hospital), Gallardo Carlos(Fundación Arturo López Pérez), Sherene Loi(The University of Melbourne), Lacerda Domicio Carvalho, Cescon David(Princess Margaret Cancer Centre), Roberto Hegg, Sally Baron-Hay, Molina Matias, Gursel Aktan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sabanathan Dhanusha, Mastura Md Yusof(Hospital Kuala Lumpur), Costa Fabiano, Alejandro Acevedo, Gomez Abuin Gonzalo, Marco Torregroza Otero, Rocha Roberto Odebrecht, Kowalwszyn Ruben, Clingan Philip, Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Begbie Stephen, David W. Cescon(Princess Margaret Hospital), de Freitas Junior Ruffo, Scalabrini Neto Antonio Orlando, Lissa Fernando Cezar Toniazzi, Norikazu Masuda(Kyoto University), Seock‐Ah Im(Seoul National University), Donatienne Taylor, Yu Joanne(Hospital Kuala Lumpur), Andrea Gombos(Inserm), Vassiliki Karantza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Danielle Charpentier, Erhan Gökmen(Ege University), Diego Kaen, Jing Zhao(Lee's Pharmaceutical (China)), Hope S. Rugo(City of Hope), Carlos H. Barrios(Eastern Cooperative Oncology Group), Esther Holgado(Vall d'Hebron Institute of Oncology), Loi Sherene(Peter MacCallum Cancer Centre), Silva Felipe, Zifang Guo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carlos Barrios(Hospital São Lucas da PUCRS), Xinni Song, F. Vidal Luis, Peter Schmid(Queen Mary University of London), Varela Mirta, Leandro Brust, Oleg Lipatov(Republican Oncological Clinical Dispensary), Carlos Gallardo(Fundación Arturo López Pérez), Hiroji Iwata(Aichi Cancer Center)
The Lancet
December 1, 2020
10.1016/s0140-6736(20)32531-9
Cited by 1,796

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k